CN101015627B - Medicine composition for treating diabetes and its preparation - Google Patents
Medicine composition for treating diabetes and its preparation Download PDFInfo
- Publication number
- CN101015627B CN101015627B CN200610122920A CN200610122920A CN101015627B CN 101015627 B CN101015627 B CN 101015627B CN 200610122920 A CN200610122920 A CN 200610122920A CN 200610122920 A CN200610122920 A CN 200610122920A CN 101015627 B CN101015627 B CN 101015627B
- Authority
- CN
- China
- Prior art keywords
- radix astragali
- water
- diabetes
- preparation
- chromium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to a Chinese medicinal composition used for treating diabetes and its preparation method. The Chinese medicinal composition comprises Astragalus root extract, medlar powder and chromium nicotinate at a wt. ratio of 500:100:1. The preparation method comprises pulverizing Astragalus root, extracting with water, filtering, concentrating, anddrying; drying medlar, pulverizing, and mixing with Astragalus root extract and chromium nicotinate. The inventive Chinese medicinal composition can effectively reduce blood sugar. The composition can be made into medicine with conventional auxiliary materials for treating diabetes.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that is used for the treatment of diabetes.
Background technology
Diabetes are a kind of chronic senile diseases, are a kind of disease that is perplexing human danger for thousands of years always, and it can make many patients fatal in a short time.Up to the beginning of this century, about 60% diabetes patient dies from diabetic coma.Diabetes all are serious day by day problems in developed country and developing country, and it has caused serious and costly consequence, comprise blind, heart disease and nephropathy etc.In developed country, the sickness rate of diabetes is more and more higher, before being more than 3 times, it has become the 4th cause of the death.Diabetes also are rejuvenation trend, and in Europe, the diabetes patient is about 1,850 ten thousand people, and by 2010, global diabetes patient's estimation can be increased to 2.15 hundred million people, and about 5% people can suffer from diabetes.Along with development of science and technology,, thoroughly conquer diabetes and remain a great problem though present diabetes patient can survive.
Chromium is one of 15 kinds of trace element of needed by human, nineteen fifty-seven, two scientists of W.Mertz and Schwarz.K find that chromium can correct the unusual carbohydrate metabolism of rat, now confirm, chromium is the essential cofactor of of insulin, forms complex and constitute glucose sugar tolerance factor in human body.The homergy that is glucose is necessary.Lack chromium in the body.The activity of insulin can be suppressed.The running speed of glucose in blood can be affected, and diabetic symptom occurs.In addition, scarce chromium can cause myopia, this is because after insulin active is suppressed, after glucose utilization is suppressed, glucose utilization is subjected to obstacle, and plasma osmotic pressure rises, thereby causes the change of eye lens and aqueous humor osmotic pressure, impel crystalline lens to become protruding, thereby the diopter increase cause myopia.Chromium and lipid metabolism are closely related, and HDL-LDL is had regulating action, generally can reduce body inner cholesterol 14%.Atherosclerosis, hypertension, coronary heart disease take place in scarce chromium easily.Therefore its physiological function has close association with invigorating, promote health, blood sugar lowering, blood fat, promotion fat oxidation, minimizing obesity, reduction body weight etc.
Chromium has used extensively abroad as supplementary, generally acknowledges that in the world trivalent chromium is a glucose sugar tolerance factor, can effectively promote secretion of insulin, is used for the treatment of type ii diabetes, blood sugar lowering, blood fat, obtains than ten-strike.
Diabetes are consistent basically with the diabetes of Chinese medicine.Chinese medicine thinks that the fundamental cause of primary disease is a cloudy body fluid deficiency consumption, scorching inclined to one side Sheng, scorching yin-damaging and Qi consuming and cause deficiency of both QI and YIN.The pathological changes mansion is dirty the most key with the spleen kidney, and waiting with spleen kidney qi two deficient syndromes clinically serves as at most, should be based on strengthening spleen, tonifying kidney, supplementing QI and nourishing YIN in the treatment.The Fructus Lycii enriching yin and nourishing kidney; Radix Astragali invigorating the spleen and replenishing QI, warm three warmers, strong taste, two medicines share the effect of playing kidney and spleen invigorating, supplementing QI and nourishing YIN altogether.Modern chemistry studies show that, contains abundant trace element chromium in the Fructus Lycii and the Radix Astragali, and therefore, it helps the human body chrome uptake.And strengthen the insulin biological effect and blood glucose is descended, be aided with the Fructus Lycii and the Radix Astragali simultaneously, pass through strengthening spleen, tonifying kidney, supplementing QI and nourishing YIN, adjust the whole spleen renal function of diabetics, improve pancreatic function, thereby promote the beta Cell of islet excreting insulin to reach the effect of blood sugar lowering.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition that is used for the treatment of diabetes, its proportioning is a Radix Astragali extract: medlar powder: nicotinic acid chromium=500: 100: 1.
Wherein Radix Astragali extract is prepared from by following method: extraction time is generally one to three time, and the number of times increase is not limit; The consumption of water is that water can not have medical material at least, and water consumption is not too much limit; Extraction time is each 0.1-24 hour, and time lengthening is not limit; Merge aqueous extract, concentrate drying promptly.
Wherein medlar powder is prepared from by following method: Fructus Lycii conventional method crushed after being dried, promptly.
Radix Astragali water extraction in the inventive method can adopt under condition or/and carry out under the ultrasound wave condition.
Drying in the inventive method, employing can be lyophilization or room temperature/heat drying, cryodesiccated temperature is a subzero, temperature is crossed and low is not limit.The temperature of heat drying can room temperature～100 ℃, and temperature is too high not to be limit.The exsiccant time can be 0.1-24 hour, and time lengthening is not limit.
Pulverizing in the inventive method is crushed into powder, and the granule size of pulverizing is not limit.
Pharmaceutical composition of the present invention has the blood sugar lowering effect, can be used for preparing the medicine for the treatment of diabetes.
The specific embodiment
The present invention is described further below in conjunction with embodiment.
Embodiment 1:
The Radix Astragali is cut into decoction pieces, decocts with water three times, and each 2 hours, add 10 times of amounts of water at every turn, medicinal liquid filters through gauze, the filtrate concentrate drying; The Fructus Lycii vacuum drying is beaten powder.
Nicotinic acid chromium and its are pressed Radix Astragali extract 500g, medlar powder 100g, nicotinic acid chromium 1g mixed, promptly.
Embodiment 2:
The Radix Astragali is cut into decoction pieces, decocts with water three times, and each 0.1 hour, add 10 times of amounts of water at every turn, medicinal liquid filters through gauze, the filtrate concentrate drying; The Fructus Lycii vacuum drying is beaten powder.
Nicotinic acid chromium and its are pressed Radix Astragali extract 500g, medlar powder 100g, nicotinic acid chromium 1g mixed, promptly.
Embodiment 3:
The Radix Astragali is cut into decoction pieces, adds flooding three times, and each 24 hours, add 15 times of amounts of water at every turn, medicinal liquid filters through gauze, the filtrate concentrate drying; The Fructus Lycii vacuum drying is beaten powder.
Nicotinic acid chromium and its are pressed Radix Astragali extract 500g, medlar powder 100g, nicotinic acid chromium 1g mixed, promptly.
Embodiment 4:
The Radix Astragali is cut into decoction pieces, supersound extraction three times, and each 10 minutes, add 10 times of amounts of water at every turn, medicinal liquid filters through gauze, the filtrate concentrate drying; The Fructus Lycii vacuum drying is beaten powder.
Nicotinic acid chromium and its are pressed Radix Astragali extract 500g, medlar powder 100g, nicotinic acid chromium 1g mixed, promptly.
Embodiment 5:
The Radix Astragali is cut into decoction pieces, microwave extraction three times, and each 10 minutes, add 15 times of amounts of water at every turn, medicinal liquid filters through gauze, the filtrate concentrate drying; The Fructus Lycii vacuum drying is beaten powder.
Nicotinic acid chromium and its are pressed Radix Astragali extract 500g, medlar powder 100g, nicotinic acid chromium 1g mixed, promptly.
Embodiment 6:
The Radix Astragali is cut into decoction pieces, decocts with water three times, and each 2 hours, add 10 times of amounts of water at every turn, medicinal liquid filters through gauze, the filtrate concentrate drying; The Fructus Lycii vacuum drying is beaten powder.
Nicotinic acid chromium and its are pressed Radix Astragali extract 100g, medlar powder 10g, nicotinic acid chromium 10g mixed, promptly.
Embodiment 7:
1) animal grouping
Healthy Wistar rat (SPF level), male, body weight 180-220g (providing) by Nanfang Medical Univ's Experimental Animal Center, the feed of freely drinking water, be divided into normal control group and modeling group at random, the modeling group is set up model as follows, again the model group animal is divided at random model control group, positive drug group after the modeling success, is subjected to the reagent object height, in, low dose group, 1 week of successive administration.
2) rat model preparation
Normal rats is irritated the stomach common drinking water every day, and high fat group rat is irritated stomach self-control fat milk (1ml/100gBW) every day sooner or later.After 2 weeks of continuous irrigation stomach fat milk, water 24h is can't help in the animal fasting, 10 tail vein injection salines of blank group, the equal tail vein injection 30mg/kgBW of all the other rats streptozotocin solution (face and use preceding preparation).Behind the administration 48h, water 12h is can't help in fasting, gets blood every 3 hours eye socket venous plexuses, according to blood sugar detection test kit time-and-motion study fasting blood sugar, and METHOD FOR CONTINUOUS DETERMINATION 3 times, fasting blood sugar 〉=16.7mmol/L's is modeling success rat.
3) blood sugar detection
After the last administration, water 12h is can't help in the animal fasting, and the eye socket venous plexus is got blood, measures blood glucose value respectively according to the method for test kit.Adopt the SPSS11.0 statistical software, analyze and respectively organize the situation of change of blood glucose value and administration front and back blood glucose value.
4) oral glucose tolerance experiment
Behind the successive administration 7 days, water 12h is can't help in the animal fasting, eye socket venous plexus measuring blood sugar of blood extracting value.Each organizes equal ig. glucose 2.0g/kgBW, and 0.5h, 1h, 2h after giving glucose from the blood sampling of eye socket venous plexus, press the method for blood glucose test kit and measure blood glucose value respectively.
The results are shown in Table 1 with table 2.
Blood glucose value relatively after table 1 administration
Annotate:
*P＜0.05vs model group
*P＜0.01vs model group
ΔP＜0.05vs is on the same group before the administration
The Δ ΔP＜0.01vs is on the same group before the administration
The experiment of table 2 oral glucose tolerance
Annotate:
*P＜0.05vs model group
Embodiment 8:
Radix Astragali extract 500g, medlar powder 100g, nicotinic acid chromium 1g are mixed, add starch 200 grams, mixing incapsulates, and gets capsule.
Embodiment 9:
With Radix Astragali extract 500g, medlar powder 100g, nicotinic acid chromium 1g mixing, add starch 200 grams, mixing is granulated, drying, the micropowder silica gel of adding 1%, tabletting gets tablet.
Claims (1)
1. a pharmaceutical composition that is used for the treatment of diabetes is characterized in that its quality proportioning is: Radix Astragali extract: medlar powder: nicotinic acid chromium=500: 100: 1; Get the Radix Astragali, extract one to three time, the consumption of water is that water can not have medical material at least; Extraction time is each 0.1-24 hour; Merge aqueous extract, concentrate drying promptly gets Radix Astragali extract; Fructus Lycii conventional method crushed after being dried promptly gets medlar powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610122920A CN101015627B (en) | 2006-10-20 | 2006-10-20 | Medicine composition for treating diabetes and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610122920A CN101015627B (en) | 2006-10-20 | 2006-10-20 | Medicine composition for treating diabetes and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101015627A CN101015627A (en) | 2007-08-15 |
| CN101015627B true CN101015627B (en) | 2010-05-12 |
Family
ID=38724956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610122920A Expired - Fee Related CN101015627B (en) | 2006-10-20 | 2006-10-20 | Medicine composition for treating diabetes and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101015627B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1131020A (en) * | 1995-03-11 | 1996-09-18 | 朱立群 | Medicine for reducing blood sugar and its preparation method and use |
| CN1234981A (en) * | 1998-05-07 | 1999-11-17 | 王富珍 | Jujube containing chromium as hypoglycemic agent |
| CN1435209A (en) * | 2002-01-28 | 2003-08-13 | 孙世凡 | Medicine for treating biabetes and preparing process thereof |
-
2006
- 2006-10-20 CN CN200610122920A patent/CN101015627B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1131020A (en) * | 1995-03-11 | 1996-09-18 | 朱立群 | Medicine for reducing blood sugar and its preparation method and use |
| CN1234981A (en) * | 1998-05-07 | 1999-11-17 | 王富珍 | Jujube containing chromium as hypoglycemic agent |
| CN1435209A (en) * | 2002-01-28 | 2003-08-13 | 孙世凡 | Medicine for treating biabetes and preparing process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101015627A (en) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103446385A (en) | Traditional Chinese medicine preparation for treating diabetic complications | |
| CN102343023A (en) | Medicinal composition and preparation method and application thereof | |
| CN104887831A (en) | Traditional Chinese medicine pressed candy and preparation method thereof | |
| CN103610752A (en) | Functional food with hypoglycemic effect and preparation method thereof | |
| CN104116990A (en) | Medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN104920753A (en) | Traditional Chinese medicine tabletting candy and preparation method thereof | |
| CN104083640B (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN103919998A (en) | Hypoglycaemic traditional Chinese medicine | |
| CN102258628B (en) | Chinese medicinal composition with lead removal promoting effect | |
| CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| CN106214787B (en) | A kind of Chinese medicine composition for treating diabetes and preparation method thereof and purposes | |
| CN100462085C (en) | Bee product tablets for diabetes and their making method | |
| CN101015627B (en) | Medicine composition for treating diabetes and its preparation | |
| CN100500174C (en) | Medicine composition used for lowering blood-sugar, preparation method and use thereof | |
| CN101455778B (en) | Traditional Chinese medicine preparation capable of reducing fever and relieving sore-throat and preparation method thereof | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
| CN100360161C (en) | Chinese medicine for treating diabets and nephritis | |
| CN104288527B (en) | It is a kind of to be used to treat Chinese medicine composition of diabetes and preparation method and application | |
| CN103750304B (en) | Weight-reducing, fat-reducing and health-protection rhizoma alismatis oral liquid and preparation method thereof | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN1192789C (en) | 'Shenhuaxiaokecha' tea and preparing method thereof | |
| CN105055851A (en) | Chinese medicinal composition for treatment of diabetes, preparation and application thereof | |
| CN100398123C (en) | Medicine for treating diabetes of blood stasis complicated kidney spleen deficiency type |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180731 Address after: 510850 No. 41 Zhenxing North Road, Shiling Town, Huadu District, Guangzhou, Guangdong Patentee after: JIANMA PHARMACEUTICAL (GUANGDONG) Co.,Ltd. Address before: 510275 No. 135 West Xingang Road, Guangdong, Guangzhou Patentee before: Sun Yat-sen University |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100512 Termination date: 20211020 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |